Sarkisian, Steven R. http://orcid.org/0000-0001-7633-2720
Ang, Robert E. http://orcid.org/0000-0002-5035-2923
Lee, Andy M.
Berdahl, John P. http://orcid.org/0000-0002-5468-7405
Heersink, Sebastian B.
Burden, James H.
Doan, Long V. http://orcid.org/0009-0008-0572-2236
Stephens, Kerry G.
Applegate, David
Kothe, Angela C. http://orcid.org/0009-0000-7971-5292
Usner, Dale W. http://orcid.org/0000-0002-2799-0652
Katz, L. Jay
Navratil, Tomas http://orcid.org/0009-0007-3577-3096
Clinical trials referenced in this document:
Documents that mention this clinical trial
Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial
https://doi.org/10.1007/s40123-024-00898-y
Article History
Received: 22 December 2023
Accepted: 23 January 2024
First Online: 12 February 2024
Declarations
:
: Steven R. Sarkisian Jr. has received research funding from Glaukos, AbbVie, Allysta Pharmaceuticals, Elios Vision, iStar Medical, Ocular Therapeutix, and Sight Sciences; consulting fees from Glaukos, Alcon, AbbVie, Bausch & Lomb, Beaver-Visitec, Icare USA, Ocular Science, and Sight Sciences; payment/honoraria for lectures/speaker’s bureau from Aerie Pharmaceuticals, Alcon, AbbVie, and Bausch & Lomb; and owns stock/stock options in Ocular Science and Sight Sciences. Robert E. Ang has received research funding from Glaukos and honoraria for lectures/speaker’s bureau from Glaukos. Andy M. Lee has received research funding from Glaukos and Elios Vision; consulting fees from Glaukos; and payment/honoraria for lectures/speaker’s bureau from Elios Vision. John P. Berdahl has received consulting fees from Alcon, Bausch & Lomb, Elios Vision, Glaukos, Imprimis, Sight Sciences, ViaLase, and Johnson & Johnson. Sebatian B. Heersink has received research funding from Glaukos, Alcon Research, Allergan, Sight Sciences, EyePoint Pharmaceuticals, Sun Pharmaceuticals, AbbVie, Oyster Point Pharma, Bausch & Lomb, Cloudbreak, Combangio, Genentech, Johnson & Johnson, Ivantis, Kala Pharmaceuticals, Lenstec, Lenz, Nicox Ophthalmics, Noveome and Ocular Therapeutix; consulting fees from Carl Zeiss Meditec Cataract Technology, Bausch & Lomb, and Rayner Intraocular Lenses; and payment/honoraria for lectures/speaker’s bureau from Iridex Corporation. James H. Burden has received research funding from Glaukos. Long V. Doan, Kerry G. Stephens, David Applegate, Angela C. Kothe, Dale W. Usner, L. Jay Katz, and Tomas Navratil are employees of Glaukos Corporation and may have received stock and/or stock options.
: Human subjects were included in this trial. The trial was undertaken in accordance with the tenets of the Declaration of Helsinki, and with approval of the relevant institutional review board/independent ethics committee (Western Institutional Review Board, Puyallup, Washington [reference number 20180735] or Wills Eye Hospital Institutional Review Board, Philadelphia, Pennsylvania [reference number 18–763] for sites in the USA, and St. Cabrini Medical Center – Asian Eye Institute Ethics Review Committee, Makati City, Philippines [reference number 2018–023] for the single site in the Philippines). All subjects provided informed consent to participate in the study.